• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    ATAI Life Sciences N.V. - Common Shares (NQ: ATAI )

    1.230 +0.030 (+2.50%)
    Streaming Delayed Price Updated: 1:00 PM EST, Dec 24, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 758,299
    Open 1.200
    Bid (Size) 1.200 (255)
    Ask (Size) 1.230 (100)
    Prev. Close 1.200
    Today's Range 1.185 - 1.250
    52wk Range 1.030 - 2.850
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Pfizer, Moderna, Novavax Take A Beating After Trump Taps Kennedy To Head Up HHS
    President-elect Donald Trump tapped widely known vaccine skeptic Robert F. Kennedy Jr. to lead the Department of Health and Human Services. 
    Via Investor's Business Daily
    Topics Government
    Exposures Political
    AI And Psychedelics: A Marriage Made In Heaven For Mental Health Care?
    AI and psychedelic medicine are merging, with research showing AI's role in drug discovery, trials, and personalized mental health care. 
    Via Benzinga
    Topics Artificial Intelligence
    Exposures Artificial Intelligence

    Performance

    YTD
    -27.22%
    -27.22%
    1 Month
    -26.79%
    -26.79%
    3 Month
    +4.24%
    +4.24%
    6 Month
    -8.89%
    -8.89%
    1 Year
    -8.89%
    -8.89%

    More News

    Read More
    Atai Q3 Report: Strong Cash Position, Clinical Pipeline Growth
    Via Benzinga
    Exposures Product Safety
    atai Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
    From atai Life Sciences
    Via GlobeNewswire
    atai Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit
    From atai Life Sciences
    Via GlobeNewswire
    Could Psilocybin Be A Game-Changer For Millions Battling Depression? New Study Says Yes
    Via Benzinga
    Psychedelics 2.0: Companies Explore Safer, More Targeted Therapies
    Via Benzinga
    Psychedelic Drug Stocks +6% Last Week Vs. -13% Previous Week
    Via Talk Markets
    MDMA Therapy For PTSD Faces FDA Delay: Are There Other Ways Forward?
    Via Benzinga
    Exposures Product Safety
    Psychedelic Compound-Based Drug Stocks Portfolio -13% W/e Sept. 6th
    Via Talk Markets
    Our Psychedelic Compound-Based Clinical-Stage Drug Stocks Portfolio Was Down 16% In August
    Via Talk Markets
    Psychedelic Drugs Market Set To Grow By $1.37B By 2028, Driven By Mental Health Disorders And AI Integration
    Via Benzinga
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
    From atai Life Sciences
    Via GlobeNewswire
    Largest Psychedelic Compound -Based Clinical-Stage Drug Stocks Up 6% Last Week
    Via Talk Markets
    Psychedelic Compound-Based Drug Stocks Portfolio: Up 17.5% In July; Down 19% MTD
    Via Talk Markets
    Atai's DMT Depression Drug Shows Promise, Prepares For Phase II Trial And Future Collaboration With Pharma Giant
    Via Benzinga
    ATAI Stock Earnings: ATAI Life Sciences Misses EPS for Q2 2024
    Via InvestorPlace
    atai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
    From atai Life Sciences
    Via GlobeNewswire
    atai Life Sciences Announces Positive Preliminary Results from Phase 1b Trial of VLS-01 (Buccal Film DMT)
    From atai Life Sciences
    Via GlobeNewswire
    atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth Conference
    From atai Life Sciences
    Via GlobeNewswire
    EXCLUSIVE: Legal Magic Mushroom Products Will Be Sold In Jamaica As Psilocybin Products Hit Pharmacy Shelves
    Via Benzinga
    Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD
    Via Talk Markets
    3 Dirt-Cheap Drug Developers With Blockbuster Potential
    Via InvestorPlace
    3 Next-Gen Drug Stocks Exploring Psychedelic Frontiers
    Via InvestorPlace
    3 Psychedelic Stocks to Ride to the Moon and Beyond
    Via InvestorPlace
    Exposures Product Safety
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.